24/7 Market News Snapshot 02 April, 2025 – AngioDynamics, Inc. (NASDAQ:ANGO)

April 2, 2025

DENVER, Colo., 02 April, 2025 (247marketnews.com) – (NASDAQ:ANGO) are discussed in this article.
AngioDynamics, Inc. (ANGO) has opened trading today at $10.91, currently showing a notable rise to $10.639, representing an increase of approximately 10.13% from the previous close of $9.66. With trading volume reaching 1.20 million shares, the upward momentum reflects growing investor interest. Technical indicators suggest a potential bullish trend, which will depend on sustained volume and price consolidation. As market optimism builds around the company’s financial outlook and potential catalysts, investors are advised to keep an eye on key resistance levels at $11.00 and support at $10.00 to better understand future price movements.

In related developments, AngioDynamics has announced strong financial results for the third quarter of fiscal year 2025, showcasing robust performance with net sales of about $72 million, marking a year-over-year growth of 9.2%. This growth is significantly driven by the company’s Med Tech segment, which recorded a remarkable 22.2% increase, underscoring heightened market demand for innovative medical solutions, particularly in vascular health and cancer treatment.

The commitment to operational efficiency is evident as the company achieved a gross margin of 54% and recorded an adjusted EBITDA of $1.3 million, highlighting its dedication to sustainable profitability amidst ongoing industry challenges. Critical advancements have also been made in clinical research, notably with the initiation of the AMBITION BTK randomized control trial aimed at assessing the Auryon Atherectomy System’s efficacy for patients with critical limb ischemia. Furthermore, the FDA’s 510(k) clearance of the NanoKnife System expands treatment options for prostate tumors.

President and CEO Jim Clemmer expressed enthusiasm regarding the company’s trajectory, stating, “Our latest performance is a testament to the transformation we’ve undergone, focusing on fast-growing MedTech markets. We’re poised for continued profitable growth and plan to enhance our high-impact initiatives while addressing evolving patient needs.” In light of these results, AngioDynamics is raising its fiscal year guidance for net sales and adjusted EBITDA, reaffirming its commitment to delivering innovative solutions that enhance patient outcomes and improve healthcare efficiency.

Related news for (ANGO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.